valentinemasson wrote: Aristotle is Greek, meaning, the best. James does believe that Aristotle is leaps and bounds ahead of competitors who have single panel tests. Others claim to have 50 cancers in one test. These are years away from from hoping to come even close to the efficacy of Aristotle.
In the following links, is mention of beginning commercialization by the end of this year. It`s a process not an end all. Time is needed, as all eyes are on Covid and with the new strain in the UK even more so. Cancer isn`t going away. Hospitals are delaying treatments as resources are strained. Having a test that identifies 10 cancers from a single sample of blood including the first ever Pan C at stage 1 is an incredible feat. This stock has been played on it`s history, and doubting Thomas`s will wish they had seen the big picture instead of staying stuck in the past.
Here`s a read for you , times 2.
Early cancer detection Stage looks to launch in Q! 2021 Be well everyone.
Yes Valentine, and the best it is - as shareholders we are about to find out what it means to be part of such a revolutionary technology.
The Corporate Recap impressively summarizes what longs talk about here on a daily basis - the only point of concern for me is:
- Validation of Aristotle as a Lab Developed Test (“LDT”) is underway.
I state this because it is the only invariable that could potentially delay any Q1 rollout as a validation process is just that - a "process" beyond the company's control. There has been no information pointing to problems with this so fingers crossed that all goes smoothly.
As for today's sp, its a real head scratcher given money in the bank, revenue earned and revenue being earned as we speak. There are so many positives and so few negatives around this company that it is indeed perplexing as to why investors are not loading up daily here.